United States Financial Markets News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Search entities
Discover all 32,649 supported financial entities for United States financial markets here.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 990,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "bcc6b3d4-e01a-425a-8127-d386061e2fbb",
"title": "Gilead Sciences (GILD) Reports Positive Results for Trodelvy Combo in Breast Cancer Study",
"description": "Gilead Sciences' Trodelvy shows promising results in a Phase 3 trial when paired with Merck's Keytruda. Average analyst price target for GILD suggests a",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Gilead Sciences' Trodelvy shows promising results in a Phase 3 trial when paired with Merck’s Keytruda.\n\nAverage analyst price target for GILD suggests a pote...",
"url": "https://www.gurufocus.com/news/2899947/gilead-sciences-gild-reports-positive-results-for-trodelvy-combo-in-breast-cancer-study",
"image_url": "https://static.gurufocus.com/logos/0C000007VR.png?20",
"language": "en",
"published_at": "2025-05-31T14:55:41.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 89.14494,
"sentiment_score": 0.078686,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em>' Trode[+314 characters]",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD)[+283 characters]",
"sentiment": -0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts' Price Projections\n[+269 characters]",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "Investors can explore more detailed esti[+293 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The estimated GF Value for <em>Gilead</e[+321 characters]",
"sentiment": 0.8144,
"highlighted_in": "main_text"
},
{
"highlight": "For further insights, visit the <em>Gile[+59 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD) Reports Positive Results for Trodelvy Combo in Breast Cancer Study",
"sentiment": -0.2023,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "397c2098-b811-44a8-9ba7-2a6966e5b96e",
"title": "Gilead Sciences Inc (GILD) Announces Promising Results for Trodelvy and Keytruda Combination in Breast Cancer Treatment | GILD stock news",
"description": "Summary Gilead Sciences Inc (GILD) has announced that its drug Trodelvy® (sacituzumab govitecan-hziy), when combined with Keytruda® (pembrolizumab), significa",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Summary\n\nGilead Sciences Inc (GILD, Financial) has announced that its drug Trodelvy® (sacituzumab govitecan-hziy), when combined with Keytruda® (pembrolizumab...",
"url": "https://www.gurufocus.com/news/2899943/gilead-sciences-inc-gild-announces-promising-results-for-trodelvy-and-keytruda-combination-in-breast-cancer-treatment-gild-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:01:29.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 106.39114,
"sentiment_score": -0.56015,
"highlights": [
{
"highlight": "Summary\n\n<em>Gilead</em> <em>Sciences</e[+342 characters]",
"sentiment": -0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> <em>Inc</em> (GILD) Announces Promising Results for Trodelvy and Keytruda Combination in Breast Cancer Treatment | GILD stock news",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "GILDD.BA",
"name": "GILEAD SCIENCES",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 94.42236,
"sentiment_score": -0.56015,
"highlights": [
{
"highlight": "Summary\n\n<em>Gilead</em> <em>Sciences</e[+333 characters]",
"sentiment": -0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> Inc (GILD) Announces Promising Results for Trodelvy and Keytruda Combination in Breast Cancer Treatment | GILD stock news",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "876385dc-a25d-43b0-8b64-188ef12d8a28",
"title": "Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer",
"description": "Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progre",
"keywords": "GuruFocus, Article, News, Business Wire, NAS:GILD",
"snippet": "Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progres...",
"url": "https://www.gurufocus.com/news/2899927/trodelvy-plus-keytruda-reduces-risk-of-disease-progression-or-death-by-35-versus-keytruda-and-chemotherapy-in-firstline-pdl1-metastatic-triplenegative-breast-cancer",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 35.270554,
"sentiment_score": -0.16755,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em>, <em>I[+357 characters]",
"sentiment": -0.802,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Gilead</em> <em>Sciences</em>\n[+225 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Trodelvy, Gilead and the Gilead logo are[+191 characters]",
"sentiment": -0.4824,
"highlighted_in": "main_text"
},
{
"highlight": "For more information about Gilead, pleas[+265 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.88321,
"sentiment_score": -0.4438,
"highlights": [
{
"highlight": "KEYTRUDA® is a registered trademark of [+322 characters]",
"sentiment": -0.8876,
"highlighted_in": "main_text"
},
{
"highlight": "About the ASCENT-04/KEYNOTE-D19 Study\n\nI[+180 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRKD.BA",
"name": "MERCK & CO INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 10.883251,
"sentiment_score": -0.4438,
"highlights": [
{
"highlight": "KEYTRUDA® is a registered trademark of [+322 characters]",
"sentiment": -0.8876,
"highlighted_in": "main_text"
},
{
"highlight": "About the ASCENT-04/KEYNOTE-D19 Study\n\nI[+180 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILDD.BA",
"name": "GILEAD SCIENCES",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 32.461277,
"sentiment_score": -0.16755,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em>, Inc. [+330 characters]",
"sentiment": -0.802,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Gilead</em> <em>Sciences</em>\n[+216 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Trodelvy, Gilead and the Gilead logo are[+182 characters]",
"sentiment": -0.4824,
"highlighted_in": "main_text"
},
{
"highlight": "For more information about Gilead, pleas[+265 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.SN",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.883226,
"sentiment_score": -0.4438,
"highlights": [
{
"highlight": "KEYTRUDA® is a registered trademark of [+322 characters]",
"sentiment": -0.8876,
"highlighted_in": "main_text"
},
{
"highlight": "About the ASCENT-04/KEYNOTE-D19 Study\n\nI[+180 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "2019a865-9d25-4977-ac19-ace4217cad96",
"title": "Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer | GILD Stock News",
"description": "Gilead Sciences (GILD) unveils breakthrough results from its Phase 3 trial for metastatic triple-negative breast cancer (TNBC). The combination of Trode",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Gilead Sciences (GILD, Financial) unveils breakthrough results from its Phase 3 trial for metastatic triple-negative breast cancer (TNBC).\n\nThe combination of T...",
"url": "https://www.gurufocus.com/news/2899921/trodelvy-plus-keytruda-reduces-risk-of-disease-progression-or-death-by-35-versus-keytruda-and-chemotherapy-in-firstline-pdl1-metastatic-triplenegative-breast-cancer-gild-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000007VR.png?20",
"language": "en",
"published_at": "2025-05-31T13:16:09.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GIS.DE",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 43.566433,
"sentiment_score": 0.1901,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+316 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em>, <em>I[+149 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 43.56643,
"sentiment_score": 0.1901,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+316 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em>, <em>I[+149 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD.MX",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 43.566147,
"sentiment_score": 0.1901,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+316 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em>, <em>I[+149 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILDD.BA",
"name": "GILEAD SCIENCES",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 44.66799,
"sentiment_score": 0.1901,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+316 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em>, Inc. [+140 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "f5a0ebdb-1877-4a86-b38d-97fb17f9e92c",
"title": "Deutsche Bank Upgrades Southwest Airlines (LUV) to Buy",
"description": "Summary:\n Deutsche Bank upgrades Southwest Airlines to a Buy due to strategic changes and potential growth. Average price target suggests potential downsi",
"keywords": "GuruFocus, Article, News, GuruFocus News, LUV",
"snippet": "Summary:\n\nDeutsche Bank upgrades Southwest Airlines to a Buy due to strategic changes and potential growth.\n\nAverage price target suggests potential downside, t...",
"url": "https://www.gurufocus.com/news/2899946/deutsche-bank-upgrades-southwest-airlines-luv-to-buy",
"image_url": "https://static.gurufocus.com/logos/0C00000955.png?20",
"language": "en",
"published_at": "2025-05-31T14:55:24.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "LUV",
"name": "Southwest Airlines Co.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 87.23694,
"sentiment_score": 0.133333,
"highlights": [
{
"highlight": "Summary:\n\nDeutsche Bank upgrades <em>Sou[+371 characters]",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "Analyst Price Targets and Implications\n\n[+296 characters]",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "For further details, investors can visit[+298 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Exploring the GF Value Estimate\n\nDelving[+242 characters]",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "For in-depth data, investors should chec[+89 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Deutsche Bank Upgrades <em>Southwest</em> <em>Airlines</em> (LUV) to Buy",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "06079ab3-efc3-4d77-addb-42429a44dbe6",
"title": "Pfizer, Arvinas to seek FDA nod for cancer therapy in H2 (PFE)",
"description": "Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more here.",
"keywords": "",
"snippet": "Pfizer (NYSE:PFE) and Arvinas (NASDAQ:ARVN) announced Saturday their plans to submit a new drug application with the Food and Drug Administration (FDA) in H2 20...",
"url": "https://seekingalpha.com/news/4454039-pfizer-arvinas-seek-fda-nod-cancer-therapy-h2",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178648915/image_2178648915.jpg?io=getty-c-w750",
"language": "en",
"published_at": "2025-05-31T14:02:41.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "ARVN",
"name": "Arvinas, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 57.62878,
"sentiment_score": -0.48895,
"highlights": [
{
"highlight": "Pfizer (NYSE:PFE) and <em>Arvinas</em> ([+253 characters]",
"sentiment": -0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Pfizer, <em>Arvinas</em> to seek FDA nod for cancer therapy in H2 (PFE)",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "727adca4-03df-461f-b2b6-d794c21bc248",
"title": "Regeneron Pharmaceuticals Inc (REGN) Announces Promising Phase 3 Trial Results for Libtayo in High-Risk CSCC | REGN stock news",
"description": "Summary Regeneron Pharmaceuticals Inc (REGN) has announced promising results from its Phase 3 C-POST trial, evaluating the PD-1 inhibitor Libtayo® (cemiplimab)",
"keywords": "GuruFocus, Article, News, GuruFocus News, REGN",
"snippet": "Summary\n\nRegeneron Pharmaceuticals Inc (REGN, Financial) has announced promising results from its Phase 3 C-POST trial, evaluating the PD-1 inhibitor Libtayo® ...",
"url": "https://www.gurufocus.com/news/2899945/regeneron-pharmaceuticals-inc-regn-announces-promising-phase-3-trial-results-for-libtayo-in-highrisk-cscc-regn-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:01:57.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 103.061874,
"sentiment_score": 0.37095,
"highlights": [
{
"highlight": "Summary\n\n<em>Regeneron</em> <em>Pharmace[+241 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</em> <em>Inc</em> (REGN) Announces Promising Phase 3 Trial Results for Libtayo in High-Risk CSCC | REGN stock news",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "823164da-ec1c-48cf-be21-2962d5bdd948",
"title": "Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing",
"description": "Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and",
"keywords": "GuruFocus, Article, News, Marketwired, REGN",
"snippet": "Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)\n\nLibtayo also demonstrated 80% and...",
"url": "https://www.gurufocus.com/news/2899929/libtayo-cemiplimab-phase-3-data-in-the-adjuvant-treatment-of-postsurgical-highrisk-cutaneous-squamous-cell-carcinoma-cscc-have-potential-to-be-practicechanging",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "0R2M.L",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 19.57739,
"sentiment_score": -0.075325,
"highlights": [
{
"highlight": "., May 31, 2025 (GLOBE NEWSWIRE) -- <em>[+264 characters]",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "You may also report side effects to <em>[+128 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements and Use of Di[+219 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Financial and other information about Re[+232 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.576618,
"sentiment_score": -0.075325,
"highlights": [
{
"highlight": "., May 31, 2025 (GLOBE NEWSWIRE) -- <em>[+264 characters]",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "You may also report side effects to <em>[+128 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements and Use of Di[+219 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Financial and other information about Re[+232 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN34.SA",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.575602,
"sentiment_score": -0.075325,
"highlights": [
{
"highlight": "., May 31, 2025 (GLOBE NEWSWIRE) -- <em>[+264 characters]",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "You may also report side effects to <em>[+128 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements and Use of Di[+219 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Financial and other information about Re[+232 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "7a204204-ec07-467a-84b4-9dde533d59d9",
"title": "Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing | REGN Stock News",
"description": "Libtayo® (cemiplimab) Phase 3 trial shows 68% reduction in disease recurrence or death risk for high-risk CSCC after surgery. Trial reveals 87% disease",
"keywords": "GuruFocus, Article, News, GuruFocus News, REGN",
"snippet": "Libtayo® (cemiplimab) Phase 3 trial shows 68% reduction in disease recurrence or death risk for high-risk CSCC after surgery.\n\nTrial reveals 87% disease-free s...",
"url": "https://www.gurufocus.com/news/2899915/libtayo-cemiplimab-phase-3-data-in-the-adjuvant-treatment-of-postsurgical-highrisk-cutaneous-squamous-cell-carcinoma-cscc-have-potential-to-be-practicechanging-regn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000008R4.png?20",
"language": "en",
"published_at": "2025-05-31T13:15:27.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.920944,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN.MX",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.919144,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0R2M.L",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 40.91459,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN34.SA",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.910954,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "611a224c-4099-4900-baa5-b0c907a34d74",
"title": "Tempus AI Inc (TEM) Launches Fuses Program to Revolutionize Precision Medicine | TEM stock news",
"description": "Summary Tempus AI Inc (TEM), a leader in AI-driven precision medicine, announced the launch of its Fuses program, designed to leverage its extensive proprietary",
"keywords": "GuruFocus, Article, News, GuruFocus News, TEM",
"snippet": "Summary\n\nTempus AI Inc (TEM, Financial), a leader in AI-driven precision medicine, announced the launch of its Fuses program, designed to leverage its extensive...",
"url": "https://www.gurufocus.com/news/2899941/tempus-ai-inc-tem-launches-fuses-program-to-revolutionize-precision-medicine-tem-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:00:47.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TEM",
"name": "Tempus AI Inc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 108.49646,
"sentiment_score": 0.39598,
"highlights": [
{
"highlight": "Summary\n\n<em>Tempus</em> <em>AI</em> <em[+205 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Financial Analyst Perspective\n\nFrom a fi[+176 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nAs [+308 characters]",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "The Fuses program is an initiative by <e[+322 characters]",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Tempus</em> <em>AI</em> <em>Inc</em> (TEM) Launches Fuses Program to Revolutionize Precision Medicine | TEM stock news",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "0179765b-45fc-46b0-9be3-ede1c187d90f",
"title": "Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model",
"description": "Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of it",
"keywords": "GuruFocus, Article, News, Business Wire, NAS:TEM",
"snippet": "Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its...",
"url": "https://www.gurufocus.com/news/2899935/tempus-introduces-fuses-a-program-designed-to-transform-therapeutic-research-and-build-the-largest-diagnostic-platform-using-its-novel-foundation-model",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:00:03.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TEM",
"name": "Tempus AI Inc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 32.17685,
"sentiment_score": 0.4939,
"highlights": [
{
"highlight": "<em>Tempus</em> <em>AI</em>, <em>Inc</em[+180 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "85d21a96-9327-40f5-97da-9138b10c066b",
"title": "Best Stock to Buy Right Now: Apple vs. Chipotle",
"description": "Chipotle has had more consistent annual growth rates than Apple. Meanwhile, Apple is currently right in the crosshairs of more tariffs. The clearer path for future growth at Chipotle makes it more appealing.",
"keywords": "Chipotle, Apple, revenue growth, Apple TV, growth rates",
"snippet": "Key Points\n\nChipotle has had more consistent annual growth rates than Apple.\n\nMeanwhile, Apple is currently right in the crosshairs of more tariffs.\n\nThe cleare...",
"url": "https://finance.yahoo.com/news/best-stock-buy-now-apple-140000064.html",
"image_url": "https://s.yimg.com/ny/api/res/1.2/_dP6bpGRo0ArQsstAqodWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/df0eb1d905ae00645da5e2b32236e440",
"language": "en",
"published_at": "2025-05-31T14:00:00.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "AAPL",
"name": "Apple Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 35.541435,
"sentiment_score": 0.73665,
"highlights": [
{
"highlight": "Key Points\n\nChipotle has had more consis[+126 characters]",
"sentiment": 0.4391,
"highlighted_in": "main_text"
},
{
"highlight": "The clearer path for future growth at Ch[+311 characters]",
"sentiment": 0.8379,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Apple</em>, in comparison, posted a [+326 characters]",
"sentiment": 0.7684,
"highlighted_in": "main_text"
},
{
"highlight": "Different stages in life\n\n<em>Apple</em>[+267 characters]",
"sentiment": 0.8516,
"highlighted_in": "main_text"
},
{
"highlight": "Initiatives like <em>Apple</em> TV+ have[+289 characters]",
"sentiment": 0.886,
"highlighted_in": "main_text"
},
{
"highlight": "Best Stock to Buy Right Now: <em>Apple</em> vs. Chipotle",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "1b99f129-7dd5-4755-af00-bc8b660384ba",
"title": "Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model | TEM Stock News",
"description": "Tempus AI, Inc. (TEM) launches Fuses program, leveraging its vast dataset for advanced diagnostic insights. The Fuses initiative aims to enhance precisi",
"keywords": "GuruFocus, Article, News, GuruFocus News, TEM",
"snippet": "Tempus AI, Inc. (TEM, Financial) launches Fuses program, leveraging its vast dataset for advanced diagnostic insights.\n\nThe Fuses initiative aims to enhance pre...",
"url": "https://www.gurufocus.com/news/2899924/tempus-introduces-fuses-a-program-designed-to-transform-therapeutic-research-and-build-the-largest-diagnostic-platform-using-its-novel-foundation-model-tem-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T13:45:21.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TEM",
"name": "Tempus AI Inc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 46.76872,
"sentiment_score": 0.25,
"highlights": [
{
"highlight": "<em>Tempus</em> <em>AI</em>, <em>Inc</em[+339 characters]",
"sentiment": 0.25,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "9acf09b4-8101-4391-a58e-1b0799da52bf",
"title": "Notable analyst calls this week: Southwest Airlines, Regeneron and Nvidia among top picks",
"description": "Wall Street updates: Discover analysts' top stock upgrades, downgrades, and key market insights, featuring Nvidia, Southwest Airlines, Salesforce, and more.",
"keywords": "",
"snippet": "The S&P500 (SP500)closed in the red, after the week witnessed muted inflation data, a court striking down President Trump's April tariffs and earnings reports f...",
"url": "https://seekingalpha.com/news/4453945-notable-analyst-calls-this-week-southwest-airlines-regeneron-and-nvidia-among-top-picks",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2185337728/image_2185337728.jpg?io=getty-c-w750",
"language": "en",
"published_at": "2025-05-31T13:35:13.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVDA",
"name": "NVIDIA Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 42.218803,
"sentiment_score": 0.10115,
"highlights": [
{
"highlight": "The S&P500 (SP500)closed in the red, aft[+252 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Notable analyst calls this week: Southwest Airlines, Regeneron and <em>Nvidia</em> among top picks",
"sentiment": 0.2023,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "2a158005-d4bb-46f2-a50a-72e3bb7c4dbc",
"title": "エポスカードの外貨事務手数料が3.85％に改悪！代わりのお得なクレジットカード等を解説",
"description": "エポスカードは2025年7月1日(火)から、外貨事務手数料を改悪します。 Visa決済センターにて2025年7 ...",
"keywords": "",
"snippet": "エポスカードは2025年7月1日(火)から、外貨事務手数料を改悪します。\n\nVisa決済センターにて2025年7月1日から処理された?...",
"url": "https://matsunosuke.jp/post-215441/",
"image_url": "https://i0.wp.com/matsunosuke.jp/wp-content/uploads/2021/03/d861355b4446dc7e7833b0e7d8054ed8.png?fit=546%2C276&ssl=1",
"language": "ja",
"published_at": "2025-05-31T13:23:46.000000Z",
"source": "matsunosuke.jp",
"relevance_score": null,
"entities": [
{
"symbol": "SONY",
"name": "Sony Group Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 11.547972,
"sentiment_score": null,
"highlights": [
{
"highlight": "ANAマイレージクラブ / <em>Sony</[+788 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "公式サイトANAマイレージクラ?[+715 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "外貨建て決済のポイント還元?[+835 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "外貨建て決済のポイント還元?[+724 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "海外旅行でおすすめのクレジ?[+735 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "その他、ソニー銀行のデビッ?[+805 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "公式サイトANAマイレージクラ?[+613 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "us",
"total_documents": 1437,
"sentiment_avg": 0.27711116059873014
}
]
}
Other details
Entity count
- 32,649